US and UK Finalize Tariff-Free Agreement on Drugs.

The UK and US have hammered out a major bilateral deal that will preserve no duties on UK drug products going into the US market.

Key Provisions of the Deal

Under the terms of the agreement, the UK has committed to raise spending on pharmaceuticals through the public health system. This pledge ensures that duties on these vital products will be held at zero for a period of three years.

This development follows earlier warnings to dramatically increase duties on branded drug imports, with figures floated up to 100%.

"This deal between the Britain bolsters the international landscape for new treatments and brings much-needed equity to transatlantic medicine commerce," an announcement said.

Commercial Impact

Pharmaceuticals represent one of the Britain's most significant export categories to the US, which is clearly the biggest destination for large companies like GSK and AstraZeneca.

Export figures show that in the 12 months leading up to September, the UK sold drugs worth billions to the US. This value accounted for nearly one-fifth of all goods exports in that span.

"This guarantee secures employment, stimulates funding and paves the way for the UK to establish itself as a global hub for medical research," the Business and Trade Secretary commented.

Detailed NHS Changes

The pact entails several notable pledges from the British government:

• Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
• Increased NHS Spending: There is a goal to increase overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
• Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. In the past, repayments were more than 20%.

Industry Background

The deal takes place against a long-running row between the sector and the British authorities over medicine costs and NHS adoption.

This friction were heightened by arguments that US consumers were paying several times more for the same drugs than people in the Britain and the EU.

In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while substantial expansions have been announced toward projects in the United States.

One official acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.